Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07485855 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Chronic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07485855 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Chronic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07485855 clinical trial report covering Influenza Vaccine, Adjuvanted(Seqirus GmbH), Phase 3, endpoints, sponsor, geography, readout timing and developm
Read →
NCT07484217 Solriamfetol Hydrochloride Excessive Daytime Sleepiness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07484217 Solriamfetol Hydrochloride Excessive Daytime Sleepiness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07484217 clinical trial report covering Solriamfetol Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261066 Artificial Bear Bile Powder Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261066 Artificial Bear Bile Powder Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20261066 clinical trial report covering Artificial Bear Bile Powder, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486687 Pembrolizumab Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486687 Pembrolizumab Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486687 clinical trial report covering Pembrolizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486544 Dexamethasone Pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486544 Dexamethasone Pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486544 clinical trial report covering Dexamethasone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486479 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486479 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486479 clinical trial report covering Venetoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486583 Desloratadine Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486583 Desloratadine Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486583 clinical trial report covering Desloratadine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07484230 Itepekimab Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07484230 Itepekimab Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07484230 clinical trial report covering Itepekimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261012 Gadopiclenol Vascular Malformations Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261012 Gadopiclenol Vascular Malformations Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20261012 clinical trial report covering Gadopiclenol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07487727 AND-017 Anemia in chronic kidney disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07487727 AND-017 Anemia in chronic kidney disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07487727 clinical trial report covering AND-017, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07487896 Tambotatug Pelitecan Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07487896 Tambotatug Pelitecan Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07487896 clinical trial report covering Tambotatug Pelitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07488247 Chlorin-e6 Diabetic foot ulcer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07488247 Chlorin-e6 Diabetic foot ulcer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07488247 clinical trial report covering Chlorin-e6, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →